Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Patients may be eligible for this study if they:~* Are HIV-positive.~* Have chronic liver disease consistent with chronic hepatitis C.~* Have evidence of hepatitis C within the 48 weeks prior to entry.~* Are 18 to 65 years old.~* Agree to use 2 barrier methods of birth control during the study and for 6 months after stopping the medications.~* Meet 1 of the following sets of guidelines: 1) have a CD4 count of more than 100 cells/mm3 and have a viral load (level of HIV in the blood) of less than 10,000 copies/ml within 35 days prior to study entry, and have taken stable anti-HIV drugs for at least 12 weeks prior to study entry and plan to remain on the same treatment for the first 24 weeks of the study; or 2) have a CD4 count of more than 300 cells/mm3 within 35 days prior to study entry and have not taken any anti-HIV drugs in the 12 weeks prior to entry, and do not plan to start anti-HIV treatment within the first 24 weeks of study entry.~Exclusion Criteria~Patients will not be eligible for this study if they:~* Have a positive test for hepatitis B.~* Show evidence of medical conditions associated with long-term liver disease other than HCV.~* Have severe mental illness, especially depression, or have been hospitalized for mental illness within the previous 24 weeks.~* Are allergic to any of the study products.~* Have uncontrolled seizures.~* Have had or currently have any immune diseases.~* Have lung disease such that function is limited.~* Have had evidence of heart disease or certain heart problems within 24 weeks of study entry.~* Have severe retinopathy (eye disease).~* Have had a major organ transplant and still have the graft.~* Have any other severe disease or cancer that would interfere with the study.~* Have had anti-cancer or immune-regulating drugs or radiation treatment within 24 weeks of study entry or expect to need such treatment during the study.~* Have received rifampin, rifabutin, pyrazinamide, isoniazid, ganciclovir, hydroxyurea, granulocyte colony-stimulating factor (G-CSF), or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 6 weeks of study entry.~* Abuse drugs or alcohol. Patients in methadone programs may participate.~* Have a blood disorder such as thalassemia.~* Have received interferon or oral ribavirin therapy.~* Have taken an experimental drug that affects HCV, within 6 weeks of study entry.~* Need to use during the study any of the drugs prohibited by the study.~* Have had an opportunistic (AIDS-related) infection within 4 weeks of study entry.~* Are pregnant or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).